INIS - International Isotopes Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0615
+0.0015 (+2.50%)
At close: 9:39AM EDT
Stock chart is not supported by your current browser
Previous Close0.0600
Open0.0615
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0615 - 0.0615
52 Week Range0.0400 - 0.1000
Volume10,000
Avg. Volume12,877
Market Cap25.818M
Beta (3Y Monthly)-0.12
PE Ratio (TTM)N/A
EPS (TTM)-0.0040
Earnings DateNov 13, 2019 - Nov 18, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.12
Trade prices are not sourced from all markets
  • PR Newswire

    International Isotopes Inc. Announces Financial Results for The Second Quarter And Six-Months 2019

    IDAHO FALLS, Idaho, Aug. 15, 2019 /PRNewswire/ -- International Isotopes Inc. (INIS) (the "Company" or "INIS") announces its financial results for the three and six months ended June 30, 2019. Total revenue for the Company for the three months ended June 30, 2019 was $2,135,839 as compared to $2,392,306 for the same period in 2018. Total revenue for the Company for the six months ended June 30, 2019 was $4,663,691 as compared to $5,193,332 for the same period in 2018.

  • PR Newswire

    International Isotopes Inc. Announces Financial Results for the First Quarter 2019

    IDAHO FALLS, Idaho, May 16, 2019 /PRNewswire/ -- International Isotopes Inc. (INIS) (the "Company") announces its financial results for the three months ended March 31, 2019. Total revenue for the Company for the three months ended March 31, 2019 was $2,527,852 as compared to $2,801,026 for the same period in 2018. The decrease is largely the result of a revenue decrease in the Company's Radiological Services segment and this was only due to the timing field service contract work in the first quarter of 2019 compared to 2018.  Revenue for radiological services work for the balance of the year is expected to be on par with 2018.

  • PR Newswire

    International Isotopes Inc. Announces Execution Of A Contract Manufacturing Agreement With Progenics Pharmaceuticals, Inc.

    IDAHO FALLS, Idaho, April 9, 2019 /PRNewswire/ -- International Isotopes Inc. (INIS) (the "Company") has announced it has executed a manufacturing and supply agreement with Progenics Pharmaceuticals Inc. ("Progenics").  Under this agreement, the Company will provide contract manufacturing services for AZEDRA® (Ultratrace® Iobenguane I-131) and other iodine products.

  • PR Newswire

    International Isotopes Inc. Announces 2018 Year End Financial Results

    IDAHO FALLS, Idaho, March 20, 2019 /PRNewswire/ -- International Isotopes Inc. (INIS) (the "Company") announces its financial results for the fiscal year ended December 31, 2018.  The Company reported total revenue in 2018 of $10,368,823 compared to $7,420,390 in 2017, which represents an increase of approximately 40%.  The details of the performance of the Company's significant business segments are discussed below. Cobalt products sales accounted for approximately 20% of the Company's total revenue in 2018 and approximately 7% in 2017.  Revenue in this segment increased by about 302% in 2018, as compared to 2017.  The significant increase in revenue is attributed to the resumption of cobalt product sales resulting from the Company's acquisition of cobalt from an alternate supplier.  In 2015, the Company executed a ten-year production purchase agreement with the U.S. Department of Energy (DOE) for bulk cobalt produced in the Advanced Test Reactor (ATR), and material has been undergoing irradiation since that time.

  • PR Newswire

    International Isotopes Inc. Announces Financial Results For The Third Quarter 2018

    IDAHO FALLS, Idaho, Nov. 15, 2018 /PRNewswire/ -- International Isotopes Inc. (INIS) (the "Company") announces its financial results for the three and nine months ended September 30, 2018. The Company's reported net loss for the three months ended September 30, 2018, decreased by approximately 79% to $333,222, compared to a net loss of $1,582,165, for the same period in 2017.  The net loss for the nine-month period ended September 30, 2018, was $631,097 as compared to $2,970,628 for the same period in 2017, a decrease in loss of approximately 79%.  The decrease in net loss for both periods was largely the result of the overall increase in revenue in the Company's cobalt products, nuclear medicine standards, and radiological services segments, along with the reduced operating expenses as noted above.  Further detail on the performance of each of these business segments is provided in the following paragraphs.

  • PR Newswire

    International Isotopes Inc. Announces a Long-Term Supply Agreement For I-131 With The University Of Missouri Research Reactor

    IDAHO FALLS, Idaho, Nov. 13, 2018 /PRNewswire/ -- International Isotopes Inc. (INIS) (the "Company") in conjunction with the University Of Missouri Research Reactor (MURR), is pleased to announce  it has recently received its first commercial shipment of I-131 from MURR. This milestone shipment makes INIS the first distributor of the isotope utilizing a U.S. source of supply since the 1980s. "Supplying I‑131 is part of a strategic initiative by the University of Missouri and MURR to address medical isotope shortages and further the University's research mission," said David Robertson, executive director of MURR.

  • PR Newswire

    International Isotopes Inc. Is Awarded Multiple New Radiological Field Service Contracts

    IDAHO FALLS, Idaho, Oct. 2, 2018 /PRNewswire/ -- International Isotopes Inc. (INIS) (the "Company") has announced it has recently been awarded more than a dozen contracts for various types of radiological field services involving sealed radioactive source recovery operations.  The value of these contracts total more than $1.6 million dollars and most of this contract work is expected to be completed during the next six months.  The contracts were awarded by the U.S. Department of Energy (DOE) and include both domestic and international locations. International Isotopes Inc. manufactures a full range of nuclear medicine calibration and reference standards and provides radiochemicals for clinical research and life sciences.  The Company also produces bulk cobalt-60 and manufactures a variety of cobalt-60 products such as teletherapy sources, and provides a wide range of radiological field services on a contract basis to clients.